Related Experiment Video

Updated: May 9, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Combining virotherapy and angiotherapy for the treatment of breast cancer

M Bazan-Peregrino1, R C A Sainson, R C Carlisle

  • 1Department of Oncology, Old Road Campus, University of Oxford, Oxford, UK.

Cancer Gene Therapy
|July 13, 2013
PubMed

Insights

Engineered oncolytic adenovirus targets breast cancer by inhibiting vascular endothelial growth factor (VEGF) and Notch signaling. This dual approach enhanced efficacy in ER-negative tumors, doubling survival time and reducing tumor vascularization.

Area of Science:

  • Oncolytic virotherapy
  • Cancer biology
  • Tumor angiogenesis

Background:

  • Oncolytic adenoviruses offer selective cancer cell lysis.
  • Tumor growth is supported by angiogenesis (new blood vessel formation).
  • VEGF and Notch signaling pathways are crucial for angiogenesis.

Purpose of the Study:

  • To engineer an oncolytic adenovirus expressing VEGF and Notch antagonists.
  • To evaluate the combined anti-cancer and anti-angiogenic effects.
  • To assess efficacy in estrogen receptor-positive and negative breast cancer models.

Main Methods:

  • Engineered AdEHE2F adenovirus to express soluble Flt-1 (sFlt1) and soluble Dll4 (sDll4).
  • Assessed in vitro effects on endothelial cells.
  • Evaluated in vivo efficacy in ER-positive (ZR75.1) and ER-negative (MDA-231) breast cancer xenografts.

Main Results:

  • In vitro, sFlt1 inhibited endothelial proliferation, while sDll4 increased vascular branching.
  • In ER-positive tumors, AdEHE2F showed virotherapy alone; sFlt1/sDll4 did not augment efficacy.
  • In ER-negative tumors, AdEHE2F encoding sFlt1 or sDll4 doubled survival and reduced tumor vascularization.

Conclusions:

  • Combined anti-VEGF and anti-Notch strategies enhance oncolytic adenovirus efficacy in ER-negative breast cancer.
  • The enhanced efficacy is attributed to synergistic anti-tumor and anti-vascular effects.
  • This dual-targeting approach holds promise for treating specific breast cancer subtypes.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...